Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(2.86)
# 978
Out of 5,182 analysts
90
Total ratings
36.9%
Success rate
10.98%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INMB INmune Bio | Upgrades: Buy | $2 → $9 | $1.47 | +512.24% | 1 | Mar 11, 2026 | |
| XOMA XOMA Royalty | Initiates: Buy | $76 | $41.97 | +81.08% | 1 | Dec 9, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.09 | +5,955.05% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $240 | $1.43 | +16,683.22% | 1 | Dec 12, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $110 | $1.29 | +8,427.13% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $54.02 | -7.44% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.02 | +1,566.67% | 1 | Sep 30, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.28 | +993.75% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $1.89 | +3,444.97% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $43 | $24.27 | +77.17% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.40 | +309.09% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $0.78 | +861.54% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $4.34 | +245.62% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $8.89 | +327.45% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.69 | +5,697.10% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $7.23 | +591.56% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $6.06 | +3,200.33% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $19.60 | +68.41% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $40.95 | -2.32% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $0.23 | +15,800.30% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $6.32 | +406.33% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $8.30 | +827.71% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $10.08 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $73.60 | -32.07% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $1.58 | +1,988.61% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $14.74 | +76.39% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $272.75 | -89.73% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.34 | +15,817.60% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $9.52 | +120.59% | 2 | Jul 12, 2017 |
INmune Bio
Mar 11, 2026
Upgrades: Buy
Price Target: $2 → $9
Current: $1.47
Upside: +512.24%
XOMA Royalty
Dec 9, 2025
Initiates: Buy
Price Target: $76
Current: $41.97
Upside: +81.08%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.09
Upside: +5,955.05%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $240
Current: $1.43
Upside: +16,683.22%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $110
Current: $1.29
Upside: +8,427.13%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $54.02
Upside: -7.44%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.02
Upside: +1,566.67%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.28
Upside: +993.75%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $1.89
Upside: +3,444.97%
Alto Neuroscience
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $24.27
Upside: +77.17%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $4.40
Upside: +309.09%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $0.78
Upside: +861.54%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $4.34
Upside: +245.62%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $8.89
Upside: +327.45%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.69
Upside: +5,697.10%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $7.23
Upside: +591.56%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $6.06
Upside: +3,200.33%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $19.60
Upside: +68.41%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $40.95
Upside: -2.32%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $0.23
Upside: +15,800.30%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $6.32
Upside: +406.33%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $8.30
Upside: +827.71%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $10.08
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $73.60
Upside: -32.07%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $1.58
Upside: +1,988.61%
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $14.74
Upside: +76.39%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $272.75
Upside: -89.73%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.34
Upside: +15,817.60%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $9.52
Upside: +120.59%